Has Matko Kalac received payments from drug or device companies?

Yes. Drug and device makers reported $62,363 in general payments to Matko Kalac across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matko Kalac did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matko Kalac come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matko Kalac

Hematology & Oncology · Orange, CANPI 1720378763

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Kyowa Kirin, Inc. at 36.7% of the total. 2023 is the largest year on record at $30,082, more than ten times the $252 reported in 2019.

$62,363in general payments, 2019–2025

Across 73 payments — averaging $854.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kyowa Kirin, Inc.$23K
Seagen Inc.$22K
Acrotech Biopharma Inc.$9K
Incyte Corporation$4K
Gilead$2K
AstraZeneca$1K
plus $1K from 4 others

$718,121in research payments, 2019–2025

Across 72 payments — averaging $9973.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$679K
Otsuka Pharmaceutical Co., Ltd.$39K
Incyte Corporation$211

What the payments were for

Consulting fees$33,00353%
Speaking & faculty fees$15,44325%
Travel & lodging$11,08918%
Food & beverage$2,8175%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kyowa Kirin, Inc.	25	$22,879
Seagen Inc.	25	$22,148
Acrotech Biopharma Inc.	13	$8,634
Incyte Corporation	2	$4,070
Gilead	1	$1,700
AstraZeneca	3	$1,434
Janssen Research & Development, LLC	1	$749
Amgen	1	$424
Eurofins Viracor, LLC	1	$188
TG Therapeutics, Inc.	1	$137

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

POTELIGEO$22,332
ADCETRIS$21,184
Beleodaq$8,533
SANCUSO$5,240
MONJUVI$4,070
Tecartus$1,700
CALQUENCE$1,430

How this compares

$62,363 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Other hematology & oncology in Orange

Catherine CoombsOrange$786K
Arash Rezazadeh KalebastyOrange$516K
Misako NagasakaOrange$507K
Elizabeth BremOrange$335K
May ChoOrange$334K
Angela FleischmanOrange$255K
Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →